Latest Breaking News On - நடாலி லேரௌுக்ஷ - Page 4 : comparemela.com

Tetra Bio-Pharma Provides Update on Its New Drug Submission Application in Canada The addressable market is estimated to be $80M CDN by 2022 OTTAWA, ON / ACCESSWIRE / April 14, 2021 / Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have advanced the REDUVO soft gel capsules New Drug Submission (NDS) file by responding to a request for more information from Health Canada, as previously announced on March 15, 2021. This review is part of the overall requirement for Tetra to be able to sell and distribute REDUVO soft gel capsules in Canada.

Natalie lerouxTetra bio pharma incOffice of submissionsHealth canadaRegulation services providerDrug identification numberTetra bio pharmaNew drug submissionFriday aprilIntellectual propertyTherapeutic products directorateGuy chamberlandநடாலி லேரௌுக்ஷடெட்ரா உயிர் பார்மா இன்க்ஆரோக்கியம் கனடாஒழுங்குமுறை சேவைகள் வழங்குநர்